First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Biotechnology

Healthcare
$43.57 -4.87%

-$0.89 today

Market cap
$1.83B
Beta
0.00
P/E (TTM)
-6.1
EPS (TTM)
-$2.81
52W Low $14.72High $26.80

Volume 0.59M

Average 0.43M

Returns on capital

First Tracks Biotherapeutics Inc management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-57.8%

avg -41.8%

ROIC

-59.4%

avg -43.8%

ROA

-50.2%

avg -37.1%

Analysis

ROA is currently the strongest return metric at -50.2% versus its period average of -37.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Daniel R. Faga

CEO, President & DirectorUSD 1.2M46——

Paul F. Lizzul

Chief Medical OfficerUSD 795.2K5142.50K0.12%

Carlos A. Garcia

Senior Vice President of CMC.————

Beth Mueller

Senior Vice President of Human Resources————

Cailin Sibley FACR

Senior Vice President of Translational Medicine————

Monique Da Silva

Senior Vice President of Corporate Affairs————

Nicole Greene

Senior VP & General Counsel————

Nick Montemarano

Vice President of Investor Relations————

Ajim A. Tamboli

Chief Financial Officer—49——

Benjamin Stone

Chief Business Officer—3542.50K0.12%

Eric J. Loumeau

Secretary—63——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

1

$1.76M

Net Transaction Value

−$1.76M

Net selling

Most Active

Ware J. Anthony

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 2, 26

Ware J. Anthony

Direct

Sell$1.8M

Summary

Insiders reported 0 buys worth $0.00 and 1 sells worth $1.76M over the last 12 months. That adds up to net selling of $1.76M. Ware J. Anthony was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does First Tracks Biotherapeutics Inc compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about TRAX's management, answered from reported figures.

Who manages TRAX?

First Tracks Biotherapeutics Inc (TRAX) lists 11 active executives. The top listed executive is Carlos A. Garcia, Senior Vice President of CMC..

Are TRAX insiders buying or selling?

Recent insider activity shows net selling of $1.76M.